-
Mercados
athexgroup.grAthens Exchange GroupRead moreTogether for a unified, stronger European capital market.
-
Acções
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Índices
A milestone in a decade of transformationEuronext joins the CAC 40®Read moreAs of 22 September 2025, Euronext has officially joined the CAC 40®, France’s flagship blue-chip index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fundos
-
Obrigações
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Warrants & Certificados
-
Derivados
Where European Government Bonds Meet the FutureTrade Mini Bond FuturesRead moreTrade mini bond futures on main European government bonds
-
Matérias-Primas
- Vista global
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Dairy derivatives
- Salmon derivatives
- Container Freight Futures
- Entrega e liquidação
- Especificações e disposições
- Commitments of Traders (CoT) report
- Commodity brokers
Take control of unpredictable dairy pricesEuropean Dairy DerivativesRead moreFutures and options on butter and skimmed milk powder now trading.
-
Recursos
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
Nov 16 (Reuters) - Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop DNA-based medicines.
• The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics and others
• San Diego-based Seawolf and Sanofi will develop treatments for bleeding disorders and other undisclosed conditions
• Seawolf could get milestone payments and royalties
• CEO Elizabeth Alcamo told Reuters the agreement includes an upfront payment, though she declined to say how much
• Seawolf's technology, called TRIDENT, uses tiny fat particles to carry DNA into the nucleus of cells without using viruses
• The company says it can offer longer-lasting effects than RNA medicines and the option of repeat dosing that virus-based gene therapies lack
• The lead program, which has been tested only in animals, aims to build muscle and reduce fat, and could be used for obesity, muscle loss and osteoporosis
• Seawolf expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028
• But "we'll probably need to raise some additional capital" to reach that stage, Alcamo said
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)
Find it fast
Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education